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ABSTRACT  23 
Context: Menopausal hormone therapy (MHT) favorably affects bone mineral density (BMD). 24 
Whether MHT also affects bone microarchitecture, as assessed by trabecular bone score (TBS), has 25 
never been evaluated. 26 
Objective: To assess the effect of MHT on TBS and BMD before and after its withdrawal. 27 
Design: Cross-sectional study. 28 
Setting: General community.  29 
 Patients or other participants: Data from the OsteoLaus cohort (1500 women aged 50-80 years). 30 
After exclusion of women with bone-modulating treatments, 1279 women were categorized according 31 
to MHT status into current (CU), past (PU) and never (NU) users. 32 
Intervention(s): none.  33 
Main outcome measure(s): Spine TBS and BMD at lumbar spine, femoral neck and total hip were 34 
assessed by dual X-ray absorptiometry. 35 
Results:  Age- and BMI-adjusted analysis showed higher TBS values in CU vs. PU or NU 36 
(1.31±0.01, 1.29±0.01 and 1.27±0.01 respectively, p<0.001). All BMD values were significantly 37 
higher in CU vs. PU or NU. Compared to NU, PU exhibited higher lumbar spine (0.94±0.01 vs. 38 
0.91±0.01 g/cm2, p=0.017) and total hip (0.86±0.01 vs. 0.84±0.01 g/cm2, p=0.026) BMD and a trend 39 
for higher TBS (p=0.066). The 10-year loss of TBS and BMD at lumbar spine and total hip was 40 
significantly lower for both CU and PU vs. NU. MHT duration had no effect on bone parameters. In 41 
PU, the residual effect on TBS and BMD was significantly more prominent in early discontinuers (< 2 42 
years). 43 
Conclusion: MHT is associated with bone microarchitecture preservation, as assessed by TBS. The 44 
effect of MHT on TBS and BMD persists at least 2 years after withdrawal. 45 
Abstract word count: 250 words  46 
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PRECIS: A crossectional analysis of the OsteoLaus cohort showed that MHT is associated with 47 
enhanced bone density and microarchitecture and the benefits persist for at least 2 years after its 48 
withdrawal. 49 
 50 
INTRODUCTION:  51 
Osteoporosis is a systemic skeletal disease characterized by low bone mass and microarchitectural 52 
deterioration of bone tissue, resulting in increased bone fragility and susceptibility to fracture (1). 53 
Bone mineral density (BMD), measured by dual X-ray absorptiometry (DXA), is a major determinant 54 
of bone strength and fracture risk (2). Nevertheless, half of fragility fractures occur in individuals with 55 
BMD values in the osteopenic or even normal range (3), highlighting the role of other factors on bone 56 
strength, like bone microarchitecture. A noninvasive assessment of the latter has been proposed by the 57 
use of trabecular bone score (TBS). TBS is a textural index that evaluates pixel grey-level variations 58 
in the lumbar spine DXA image, providing an indirect index of trabecular microarchitecture (4). 59 
Multiple case-control studies, prospective trials (5, 6) as well as a meta-analysis (7) have shown that 60 
TBS predicts fracture risk in postmenopausal women, independently of clinical risk factors, BMD and 61 
FRAX® tool. In 2015, TBS was added in the FRAX® tool to evaluate the 10-year fracture risk.  62 
Menopausal hormone therapy (MHT) was for many years a first-line therapy in the prevention of 63 
postmenopausal osteoporosis. This practice was supported by observational data. The Women's 64 
Health Initiative (WHI) randomized trial was the first study to prove that MHT reduces the incidence 65 
of all osteoporosis-related fractures in postmenopausal women, even those at low risk of fracture (8, 66 
9). The trial concluded, however, that the bone benefits are outweighed by other adverse events, 67 
particularly an increase in breast cancer, coronary heart disease and strokes in the estrogen/progestin 68 
arm and an excess of strokes in the estrogen-only arm. These conclusions led to a diminishing clinical 69 
use of estrogen (10), regulatory bodies downgrading MHT to second-line therapeutic choice for 70 
postmenopausal osteoporosis.  71 
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However, controversy persists about the validity of these conclusions (11). Subgroup analysis of 72 
women aged 50-59 years at entry in the WHI trial showed favorable long-term outcomes for 73 
cardiovascular disease and global index of health (12, 13).  Promising evidence for protection against 74 
bone loss has been reported with lower doses of oral estrogen or transdermal administration (14). The 75 
latter causes probably less adverse vascular events (15). As a result, the latest guidelines re-establish 76 
MHT as a first-line treatment for the prevention of fracture in at-risk women before age of 60 years or 77 
within 10 years after menopause without any mandatory time limit for the duration of treatment (16). 78 
The initiation of MHT after the age of 60 years remains not recommended due to the risk of long-term 79 
complications and the existence of alternatives medications with a better safety profile. 80 
Though the positive effect of MHT on BMD is well established, there are no available data on the 81 
direct influence of MHT on TBS. A small retrospective cohort study assessed the longitudinal 82 
changes of BMD and TBS in two different states of estrogen deprivation: natural menopause and 83 
aromatase inhibitor treatment (17).  After a follow up of 2-3 years, TBS declined in both group but to 84 
a lesser extent than BMD.  85 
Given the renewed interest for MHT, we aimed to explore the effect of MHT on TBS and BMD 86 
before and after its withdrawal using data from a large cross-sectional, population-based study on 87 
osteoporosis in women conducted in Lausanne, Switzerland.  88 
MATERIAL AND METHODS: 89 
Setting: Data from the OsteoLaus study were used (18). OsteoLaus is a sub-study of the CoLaus 90 
study, an ongoing prospective study aiming to assess the determinants of cardiovascular disease using 91 
a population-based sample drawn from the city of Lausanne, Switzerland (19). Between September 92 
2009 and September 2012, all women aged between 50 and 80 years from the CoLaus study were 93 
invited to participate in the OsteoLaus study and 85% accepted. The OsteoLaus study was approved 94 
by the Institutional Ethics Committee of the University of Lausanne. All participants signed an 95 
informed consent. 96 
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At baseline, each patient had: 1. A questionnaire on potential clinical risk factors for 97 
fracture/osteoporosis (including Swiss FRAX® assessment) and on conditions affecting bone 98 
metabolism; 2. Determination of the type, dose and duration of MHT; 3. A spine (L1 to L4) and femur 99 
DXA scan using the Discovery A System (Hologic, USA); 4. A blind central processing of TBS (TBS 100 
iNsight v2.1, medimaps, France) based on a previously acquired antero-posterior spine DXA scan; 5. 101 
A vertebral fracture assessment (VFA) by two experimented clinicians using the semiquantitative 102 
approach of HK. Genant (20). 103 
Participants: 1500 women were included in the OsteoLaus cohort. 58 women were excluded from our 104 
analysis due to non-interpretable lumbar spine images (extreme BMI defined as <15 Kg/m2 or >37 105 
Kg/m2, severe spine deformations, osteosynthesis material, less than two evaluable vertebrae). 137 106 
women were excluded for current or past osteoporotic treatment other than MHT and 23 for current or 107 
past exposure to aromatase inhibitors or tamoxifen. Three others cases were excluded because of 108 
congenital hyperostosis, androgen treatment and transsexuality.  109 
According to MHT status, the remaining participants (n=1279) were divided into 3 groups: current 110 
(CU), past (PU) and never users (NU). CU were on MHT at trial entry or discontinued MHT since 111 
less than 6 months (otherwise considered as PU). CU had followed MHT for at least 6 months 112 
(otherwise considered as NU). PU followed MHT for at least 6 months (otherwise considered as NU) 113 
and discontinued MHT at least 6 months before trial entry (otherwise considered as CU). 114 
Variables: BMD at lumbar spine, femoral neck and total hip, as well as spine TBS were defined as the 115 
primary outcomes of the analysis. Age and BMI were considered as major confounders and effect 116 
modifiers. Other variables of interest were prevalence of vertebral fractures in VFA (defined as ≥ 1 117 
fracture of grade 2/3 and/or ≥ 2 fractures of grade 1), history of fragility fractures (defined as low-118 
trauma fractures, symptomatic or asymptomatically discovered on VFA), history of major 119 
osteoporotic fractures (defined as fragility fractures in vertebrae, hip, proximal humerus, distal 120 
forearm and pelvis), use of supplements (defined as current or past use of calcium and/or vitamin D). 121 
The 10-year fracture risk was calculated with the Swiss FRAX® tool. 122 
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Dietary calcium intake was assessed using a validated, semi-quantitative food frequency questionnaire 123 
(FFQ), which also includes portion size (21). This FFQ has been validated in the Geneva population 124 
(22). 125 
Plasma 25-hydroxyvitamin D levels were available for the majority of the participants (n=1204, 126 
NU=582, PU=359, CU=263) from the second CoLaus visit that took place within 6 months before the 127 
OsteoLaus visit. Plasma 25-hydroxyvitamin D level was measured using an ultra-high pressure liquid 128 
chromatography-tandem mass spectrometry system (23). The inter-day CV% was 4.6% at 40 nmol/L. 129 
Statistical analysis: Statistical analyses were conducted using Stata v14.1 (StataCorp, College Station, 130 
Texas, USA) for windows. Descriptive results were expressed as number of participants (percentage) 131 
or as average ± standard deviation. Bivariate analyses were conducted using chi-square for categorical 132 
variables and analysis of variance for continuous variables. Multivariate analyses for continuous 133 
variables were conducted using analysis of variance or multiple regression; results were expressed 134 
either as adjusted average ± standard error or as slope and (95% confidence interval). Post-hoc 135 
pairwise comparisons were performed using the method of Scheffe. The association between bone 136 
outcomes and time since MHT discontinuation was modeled by nonlinear regression in order to 137 
identify possible hinges in the relationship. For each bone parameter, the hinge and the slopes before 138 
and after the hinge (when present) were estimated and their 95% confidence levels were assessed by 139 
bootstrap with 100 replications. Statistical significance was considered for a bivariate test with a p-140 
value <0.05. 141 
RESULTS: 142 
Of the 1279 women included in the analysis, 282 (22%) were CU, 380 (30%) were PU and 617 (48%) 143 
were NU. The vast majority of participants were of Caucasian ethnicity (1256/1279, 98.2%). Their 144 
baseline characteristics according to MHT group are shown in Table 1. PU were significantly older, 145 
had a higher prevalence of fractures, took more frequently calcium and vitamin D supplements and 146 
had a higher 10-year fracture risk. The latter was no longer present after adjustment for age. No 147 
differences were found for body mass index and dietary intake of calcium. There was a significant 148 
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difference regarding plasma 25-hydroxyvitamin D levels (CU>PU>NU), which however remained 149 
slight with an average difference of 5.5 nmol/l between CU and NU.  150 
The results for the primary bone outcomes according to MHT group, both unadjusted and after 151 
adjustment for age and BMI are shown in Table 2. CU had consistently higher values of TBS and 152 
BMD at all sites compared with NU and PU in both unadjusted and adjusted models. After adjustment 153 
for age and BMI, PU showed higher lumbar spine and total hip BMD than NU (p=0.017 and p=0.026 154 
respectively). A trend in favor of PU versus NU was noted for TBS values (p=0.066). 155 
The effect of MHT was also assessed by a multivariate analysis with age as an independent variable 156 
(Table 3). The adjusted slopes for 10-year increments showed a decrease of all sites BMD and TBS 157 
loss according to MHT status: CU<PU<NU (p<0.05 for trend). Figure 1 provides a graphic 158 
representation of BMI-adjusted slopes for association of BMD and TBS with age, according to MHT 159 
group. CU exhibited significantly less steep slopes for loss of TBS as well as BMD at all sites. BMI-160 
adjusted slopes for PU were significantly less steep than the ones for NU, with the exception of the 161 
BMD at femoral neck.  162 
Table 4 shows the bone parameters according to MHT duration and time since MHT withdrawal. No 163 
association was found between MHT duration and bone outcomes in the combined CU+ PU group. In 164 
PU, all BMD and TBS values were significantly higher when the time since discontinuation was less 165 
than 2 years in comparison to more than 5 years. A multivariate regression analysis using time since 166 
MHT discontinuation as a continuous variable led to similar conclusions, whereas a hinge analysis 167 
(Table 5) allowed the identification of an inflexion point between 2 and 4 years since MHT 168 
discontinuation, beyond which the benefit of MHT on bone outcomes has disappeared. No statistically 169 
significant difference was noted between the different bone outcomes (TBS, BMD at different sites) 170 
in terms of inflexion points. 171 
DISCUSSION:  172 
To maximize anti-fracture efficacy, agents against osteoporosis should ideally have an effect on both 173 
bone mass and bone microarchitecture. TBS has emerged as a non-invasive, easily-acquired and 174 
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reliable indirect indicator of bone microarchitecture, providing an additional surrogate marker for 175 
fracture risk assessment (4). The effect of anti-osteoporotic drugs on TBS has been shown to be 176 
smaller in magnitude than the one on BMD (4, 24). In a substudy of the randomized TEAM trial, 177 
Kalder et al explored the effect of exemestane and tamoxifen on BMD and TBS in postmenopausal 178 
women with hormone-sensitive breast cancer (25). After 2 years, TBS increased by 3.3% in the 179 
tamoxifen group compared to a decrease of 2.3% in the exemestane group. The positive impact of 180 
tamoxifen on TBS could suggest a potential advantage related with its estrogenic agonist properties. 181 
This crossectional analysis of the OsteoLaus cohort demonstrates for the first time that MHT is 182 
associated with higher levels of TBS. CU presented significantly higher TBS values than NU and PU. 183 
After adjustment for age and BMI, a trend for higher TBS values in PU versus NU was observed. In 184 
the multivariate analysis, slopes for 10-year increments were significantly less steep in both CU and 185 
PU, indicating that MHT slows down the age-associated loss of TBS. Interestingly, the slopes for age-186 
associated decline in TBS were significantly more pronounced than those in spine BMD, a finding 187 
which was attributed to TBS being less influenced by age-induced osteoarthritic changes (4), which 188 
falsely elevate spine BMD. 189 
The only clinical study that has analyzed the effect of MHT on bone microarchitecture is the Kronos 190 
Early Estrogen Prevention Study (26). In a subset of this trial (MHT n=45 vs. placebo n=30), bone 191 
microarchitecture was assessed by high-resolution peripheral quantitative computed tomography at 192 
the distal radius. After 4 years of follow-up, MHT prevented the decrease of cortical volumetric 193 
BMD, as well as the increase of cortical porosity at distal radius. Nevertheless, the degradation of 194 
trabecular microarchitecture at the distal radius was not halted by MHT. No trabecular assessment of 195 
the lumbar spine was performed in the Kronos study, thus not allowing for a direct comparison with 196 
our data. It is possible that the beneficial effect of MHT on trabecular bone is not identical at all 197 
skeletal sites.  198 
Our results confirm that current MHT use is associated with higher BMD values at all relevant sites, a 199 
finding consistent with previous randomized trials as well as a meta-analysis (27). The 200 
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postmenopausal estrogen/progestin intervention (PEPI) trial investigated the effect of MHT in women 201 
in the early menopausal phase. After 3 years, those assigned to MHT regimens had an average gain of 202 
5.1% and 2.4% at spine and total hip BMD respectively, compared to a loss of 2.8 and 2.2% in the 203 
placebo group (28). In the relatively older population of the WHI trial (29), after 3 years of follow-up, 204 
the percentage difference in favor of the MHT group was 4.5% and 3.6% for BMD at lumbar spine 205 
and total hip respectively. MHT was effective despite the absence of osteoporosis at baseline (mean 206 
T-scores: -1.3 at lumbar spine, -0.94 at total hip). 207 
If the beneficial effect of MHT on BMD is well established, this is not the case for the BMD 208 
preservation after its withdrawal. Our data argue in favor of a partially persistent effect in PU, who 209 
showed higher BMD values in the age-adjusted analysis, as well as a less rapid decrease of age-210 
associated BMD loss at lumbar spine and total hip compared to NU. Further analysis confirmed that 211 
time since MHT withdrawal is a crucial factor, with early discontinuers (< 2 years) presenting with 212 
significantly higher BMD levels than the late ones (> 5 years). The inflexion point, beyond which the 213 
BMD benefit disappears, is estimated between 2-4 years.   214 
Conflicting data exist about an eventual rebound effect after MHT withdrawal resulting in rapid loss 215 
of the previously acquired benefit. Several non-randomized studies (30, 31, 32) did not find any 216 
accelerated bone loss after MHT discontinuation. In the PERF study (30), the dosage of bone 217 
remodeling markers did not show increased bone resorption following MHT withdrawal. However, in 218 
a randomized placebo-controlled trial, Greenspal et al (33) revealed significant loss of BMD (4.5%, 219 
2.4% and 1.8% at lumbar spine, femoral neck and total hip respectively) 1 year after estrogen 220 
withdrawal in comparison to alendronate discontinuation in 425 hysterectomized women, previously 221 
treated with these agents versus placebo for 2 years. The loss of BMD observed in the estrogen group 222 
was associated with an increase of bone resorption markers. Similar results were described in other 223 
trials of recently menopaused (34, 35) or older women (36). In the latter study, there were no 224 
significant BMD differences between PU and placebo group already 2 years after estrogen 225 
withdrawal.  226 
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Possible explanations for these divergent results can be hypothesized. In the PERF trial, the authors 227 
reported heterogeneous rates of bone loss with faster decrease of BMD in women with lower BMI. 228 
Trémollieres et al (35) also detected large variations among MHT withdrawers. The rate of bone loss 229 
correlated with age and vertebral BMD at the time of MHT cessation but not with BMI. Differences 230 
regarding MHT type and dose between different studies, as well as the non-assessment of 25-231 
hydroxyvitamin D status in some trials constitute additional factors possibly contributing to the 232 
contradictory results. Due to our large sample covering the whole age spectrum of post-menopausal 233 
women, we consider our results to be less dependent on individual variables, thus being reliable for 234 
generalization to clinical practice. In our cohort, the mean BMI was in the slightly overweight range 235 
without differences between groups. Plasma 25-hydroxyvitamin D levels differed slightly but 236 
remained higher than 50 nmol/l (= 20 μg/l) in all groups. Relatively high BMI and adequate plasma 237 
25-hydroxyvitamin D levels may have lessened excessive bone resorption post MHT withdrawal, in 238 
contrast to other studies.  239 
Another interesting point is the between-sites discrepancy with absence of residual effect on femoral 240 
neck, whose content is rich in cortical bone. This finding has not been reproduced in previous studies 241 
and should be considered cautiously until further evaluation, given that estrogen-deprivation states 242 
have been preferentially linked to loss of trabecular bone. 243 
BMD and TBS are surrogate markers of osteoporotic fracture risk. Consequently, given our results in 244 
favor of a residual effect in PU, we would expect decreased fracture incidence in this group in 245 
comparison with NU.  The recently published NICE guidelines (37) on the effect of MHT recency and 246 
duration on fracture incidence support this hypothesis. Indeed, after an exhaustive meta-analysis and 247 
based mostly on observational trials, the authors concluded that bone benefits of MHT seem to persist 248 
after its withdrawal; however they have vanished by 5 years since MHT discontinuation. Data derived 249 
from randomized controlled trials showed no effect of MHT duration on fracture risk, whereas some 250 
observational studies suggested additional benefits only for MHT duration longer than 10 years.  251 
In agreement with these conclusions, we did not detect any BMD differences according to MHT 252 
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duration in the combined CU+PU group. The most plausible explanation is the accelerated gain of 253 
bone density at all sites during the first 2 years of treatment, seen with MHT (29) and also described 254 
for other antiresorptives. The increase of bone density slows down during the next years of treatment 255 
with a subsequent flattening of the changes, thus constituting the overall duration of MHT a less 256 
decisive factor on bone outcomes. 257 
Our study has several limitations. First, the beginning and the end of MHT were self-reported. 258 
Second, for the same reason we could not reliably distinguish the different routes of administration of 259 
MHT (oral, transdermal, vaginal) or the type of MHT (estrogen-alone or estrogen/progestin). Third, 260 
we could not determine the dose of estrogen per participant, which can be important given the 261 
potentially dose-dependent effects on bone outcomes. On the other hand, our study has many strong 262 
points to be taken into account. The large sample of the OsteoLaus cohort allows for adequate 263 
statistical power to detect differences between groups. Another strength is the quality of the data 264 
collected in the cohorts CoLaus and OsteoLaus. Radiological tests were performed in high quality and 265 
standardized devices allowing for accurate measurement of BMD and TBS.  266 
In conclusion, we report herein for the first time that MHT is associated with better preservation of 267 
bone microarchitecture, as assessed by TBS. In addition to the well-established positive effect of 268 
MHT on BMD, the bone microarchitecture preservation probably contributes to the anti-fracture 269 
efficacy. The protective effect of MHT on BMD and TBS seems to persist after its withdrawal for at 270 
least 2 years. Given the renewed interest in MHT, our results provide encouraging informations for 271 
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Table 1: Baseline characteristics of participants according to menopausal hormone therapy status 381 
 Never (n=617) Past (n=380) Current (n=282) p-value 
Age (years) 62.1 ± 8.0 67.4 ± 6.2 64.0 ± 6.8 <0.001 
BMI (kg/m2) 25.9 ± 4.5 26.0 ± 4.2 25.3 ± 4.0 0.084 
Fractures (%)     
VFA 32 (5.2) 30 (7.9) 6 (2.1) 0.005 
All fragility 94 (15.2) 89 (23.4) 39 (13.8) 0.001 
Major osteoporotic 69 (11.2) 58 (15.3) 17 (6.0) 0.001 
Calcium intake     
Diet (mg) 954 ± 524 982 ± 506 1038 ± 571 0.102 
Supplements (%) 215 (34.9) 212 (55.8) 105 (37.2) <0.001 
Plasma 25-hydroxyvitamin D 
(nmol/L) 
51.1 ± 22.5 55.7 ± 23.1 56.6 ± 24.7 0.002 
FRAX , 10 years risk 11.2 ± 7.1 13.4 ± 7.5 10.5 ± 5.6 <0.001 
BMI, body mass index; BMD, body mineral density; TBS, trabecular bone score; VFA, vertebral 382 
fracture assessment. Results are expressed as number of participants (percentage) or as average ± 383 
standard deviation. Between groups analysis was performed by chi-square or analysis of variance. 384 
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Table 2: Bone mineral densities and trabecular bone score of the sample according to menopausal 385 
hormone therapy status 386 
 Never (n=617) Past (n=380) Current (n=282) 
Unadjusted    
BMD lumbar spine 0.91 ± 0.15 a 0.94 ± 0.17 b 0.98 ± 0.15 c 
TBS lumbar spine 1.28 ± 0.10 a 1.27 ± 0.10 a 1.31 ± 0.10 b 
BMD femoral neck 0.73 ± 0.11 a 0.73 ± 0.10 a 0.76 ± 0.11 b 
BMD total hip 0.85 ± 0.12 a 0.85 ± 0.11 a 0.89 ± 0.11 b 
Age and BMI-adjusted    
BMD lumbar spine 0.91 ± 0.01 a 0.94 ± 0.01 b 0.98 ± 0.01 c 
TBS lumbar spine 1.27 ± 0.01 a 1.29 ± 0.01 a 1.31 ± 0.01 b 
BMD femoral neck 0.72 ± 0.01 a 0.73 ± 0.01 a 0.76 ± 0.01 b 
BMD total hip 0.84 ± 0.01 a 0.86 ± 0.01 b 0.89 ± 0.01 c 
BMD, bone mineral density; TBS, trabecular bone score. Results are expressed as adjusted mean ± 387 
standard error. Between groups analysis were performed using analysis of variance. Post-hoc pairwise 388 
comparisons using the method of Scheffe; values with different superscripts are significantly different 389 
at p<0.05 for pairwise comparisons (a versus b, b versus c). 390 
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Table 3: Multivariate analysis of bone parameters according to menopausal hormone therapy status with age as an independent variable 391 
    p-value for parallelism 
 Never (n=617) Past (n=380) Current (n=282) All Current vs. never Past vs. Never 
BMD LS       
Bivariate -0.016 (-0.031; -0.001) 0.015 (-0.013; 0.043) 0.026 (-0.001; 0.052) 0.013 0.009 0.042 
BMI-adjusted -0.026 (-0.040; -0.011) 0.014 (-0.013; 0.041) 0.025 (-0.001; 0.050) <0.001 0.001 0.008 
TBS LS       
Bivariate -0.054 (-0.063; -0.045) -0.033 (-0.048; -0.017) -0.022 (-0.039; -0.005) 0.002 0.001 0.024 
BMI-adjusted -0.051 (-0.060; -0.041) -0.032 (-0.048; -0.017) -0.022 (-0.038; -0.005) 0.005 0.003 0.048 
BMD FN       
Bivariate -0.031 (-0.042; -0.020) -0.018 (-0.035; -0.001) -0.009 (-0.028; 0.010) 0.099 0.044 0.212 
BMI-adjusted -0.038 (-0.048; -0.028) -0.019 (-0.035; -0.002) -0.010 (-0.027; 0.008) 0.011 0.006 0.055 
BMD TH       
Bivariate -0.039 (-0.051; -0.028) -0.022 (-0.041; -0.004) -0.011 (-0.029; 0.008) 0.025 0.011 0.115 
BMI-adjusted -0.048 (-0.059; -0.038) -0.023 (-0.040; -0.006) -0.011 (-0.028; 0.007) <0.001 <0.001 0.012 
BMI, body mass index; BMD, bone mineral density; TBS, trabecular bone score. LS, lumbar spine; FN, femoral neck; TH, total hip. Results are expressed as 392 
adjusted slope (95% confidence interval) for a ten-year increment. Statistical analysis by analysis of covariance. 393 
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Table 4: Bone parameters according to duration of menopausal hormone therapy and time since 394 
withdrawal 395 






BMD total     
hip 
Duration of MHT (years), n=644 
[0-2] 0.92 ± 0.02 1.27 ± 0.01 0.73 ± 0.01 0.85 ± 0.01 
[2-5] 0.95 ± 0.02 1.28 ± 0.01 0.73 ± 0.01 0.87 ± 0.01 
[5+] 0.94 ± 0.01 1.28 ± 0.01 0.72 ± 0.01 0.85 ± 0.01 
P-value 0.485 0.640 0.672 0.326 
P-value for trend 0.379 0.679 0.506 0.823 
Time since withdrawal (years), n=357 
[0-2] 1.02 ± 0.03 a 1.33 ± 0.02 a 0.77 ± 0.02 a 0.90 ± 0.02 a 
[2-5] 0.93 ± 0.02 b 1.28 ± 0.01 a, b 0.71 ± 0.01 b 0.85 ± 0.01 a, b 
[5+] 0.93 ± 0.01 b 1.27 ± 0.01 b 0.72 ± 0.01 b 0.85 ± 0.01 b 
P-value 0.007 0.002 0.007 0.009 
P-value for trend 0.003 <0.001 0.005 0.002 
MHT, menopausal hormone therapy; BMD, bone mineral density; TBS, trabecular bone score; 396 
Results are expressed as adjusted mean ± standard error. Information on duration of MHT was 397 
available for the majority of current (CU, n=278) and past (PU, n=366) MHT users, consisting a total 398 
of 644 participants. Information on time since MHT discontinuation was available for the majority 399 
(n=357) of PU. Statistical analysis was performed using an ANOVA model including age, body mass 400 
index, duration of menopausal hormonal therapy and time since discontinuation. Post-hoc pairwise 401 
comparisons using the method of Scheffe; values with different superscripts are significantly different 402 




Table 5: Piecewise regression between bone parameters and time since discontinuation of menopausal hormone therapy in past users of menopausal hormone 405 
therapy 406 
 BMD lumbar spine TBS lumbar spine BMD femoral neck BMD total hip 
Unadjusted     
Hinge (years)  3.486 (-1.540 ; 8.512)  2.750 (0.612 ; 4.887)*  2.250 (1.001 ; 3.499)***  2.405 (-0.171 ; 4.981) 
Slope before hinge -0.033 (-0.094 ; 0.028) -0.032 (-0.060 ; -0.003)* -0.061 (-0.135 ; 0.014) -0.051 (-0.126 ; 0.024) 
Slope after hinge  0.001 (-0.003 ; 0.005) -0.002 (-0.004 ; 0.000)*  0.001 (-0.0004 ; 0.003)  0.000 (-0.002 ; 0.002) 
Multivariate-adjusted §     
Hinge (years)  3.468 (0.324 ; 6.613)*  2.750 (0.071 ; 5.429)*  2.282 (1.007 ; 3.557)***  3.804 (1.628 ; 5.980)*** 
Slope before hinge -0.032 (-0.089 ; 0.025) -0.028 (-0.057 ; 0.001) -0.054 (-0.113 ; 0.005) -0.022 (-0.082 ; 0.037) 
Slope after hinge  0.002 (-0.002 ; 0.006)  0.001 (-0.001 ; 0.003)  0.001 (-0.0004; 0.003)  0.002 (0.000 ; 0.003) 
The analysis was conducted on past users of menopausal hormone therapy (MHT), for which information on time since MHT discontinuation was available 407 
(n=357). BMD, bone mineral density; TBS, trabecular bone score; § adjusted on age, body mass index, and duration of menopausal hormone therapy. Non-408 
linear regression performed on the residuals following multivariate linear regression of the different bone parameters on age, body mass index, and duration 409 
of menopausal hormone therapy.*, p<0.05; **, p<0.01; ***, p<0.001.410 
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LEGEND OF FIGURE 1: 411 
Graphic representation of the body mass index-adjusted association and corresponding 95% 412 
confidence interval of bone mineral density (BMD) and trabecular bone score (TBS) with age, 413 
according to menopausal hormone therapy group: current users (CU) (light grey), past users (PU) 414 
(medium grey) and never users (NU) (dark grey). 415 
 416 
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